Article
Cardiovascular benefits and improved patient survival by rosuvastatin treatment in hemodialyis patients are determined by normalization of CRP and LDL-cholesterol - A prospective analyis of the AURORA trial.
Bengt Fellström,H. Holdaas,Alan G. Jardine,Roland E. Schmieder,Mattis Gottlow,Jonsson Eva+1 more-2011-01-01
0
TL;DRAbstract
Cardiovascular benefits and improved patient survival by rosuvastatin treatment in hemodialyis patients are determined by normalization of CRP and LDL-cholesterol - A prospective analyis of the AURORA trial.
Chat with Paper
AI Agents for this Paper
Cardiovascular benefits and improved patient survival by rosuvastatin treatment in hemodialyis patients are determined by normalization of CRP and LDL-cholesterol - A prospective analyis of the AURORA trial.
Keywords
RosuvastatinMedicineNormalization (sociology)Internal medicineCholesterolProspective cohort studyClinical trialCardiology
Chat
Click to start Chat